Topic

North Carolina

A collection of 54 issues

How to Get Cabometyx (Cabozantinib) Approved by UnitedHealthcare in North Carolina: Complete Prior Authorization Guide

Answer Box: Getting Cabometyx Covered by UnitedHealthcare in North Carolina Cabometyx (cabozantinib) requires prior authorization from UnitedHealthcare/OptumRx for all indications. The fastest path to approval: (1) Verify your plan covers specialty drugs through OptumRx, (2) Submit the UnitedHealthcare Cabometyx PA form with complete clinical documentation including diagnosis, prior therapies,
6 min read

How to Get Natpara Covered by Blue Cross Blue Shield in North Carolina: Complete Appeals Guide with Forms and Deadlines

Answer Box: Getting Natpara Covered by Blue Cross Blue Shield in North Carolina Important Update: Natpara manufacturing ended December 2024, with the Special Use Program ceasing December 31, 2025. New patient requests are typically denied due to discontinued availability. For existing patients transitioning off Natpara, focus on documenting medical necessity
6 min read

How to Get Elaprase (Idursulfase) Covered by Cigna in North Carolina: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Elaprase (Idursulfase) Covered by Cigna in North Carolina Eligibility: Cigna covers Elaprase for Hunter syndrome (MPS II) when you have confirmed enzymatic deficiency AND genetic testing showing IDS gene mutations. Fastest approval path: Submit prior authorization with both biochemical and molecular diagnostic proof, weight-based dosing calculations, and
6 min read

How to Get Vyndaqel/Vyndamax (Tafamidis) Covered by Aetna CVS Health in North Carolina: Complete Guide to Prior Authorization, Appeals, and External Review

Answer Box: Getting Tafamidis Covered by Aetna CVS Health in North Carolina Quick Path to Approval: Aetna requires prior authorization for both Vyndaqel and Vyndamax (tafamidis) with confirmed ATTR-CM diagnosis via PYP scan or biopsy, NYHA Class I-III symptoms, and specialist prescriber. First step today: Verify your 2025 formulary status—
6 min read